Takeda disappointed as NICE issue second negative draft decision for ixazomib
Company says it is determined to work collaboratively to find a solution.
Takeda has expressed its disappointment that there will be further delay before NHS patients can gain access to ixazomib (Ninlaro) for adults with relapsed or refractory (RR) multiple myeloma (MM). The National Institute for Health and Care Excellence (NICE) has issued a second, negative appraisal consultation document (ACD) for ixazomib in combination with lenalidomide and dexamethasone (IRd), for the treatment of patients who have received one or more previous therapies.
The latest draft recommendation concludes that ixazomib still does not meet all the criteria required for inclusion in the Cancer Drugs Fund (CDF). Takeda continues to be fully committed to working closely with NICE, NHS England and the myeloma community during the consultation period and will do everything in their power to secure patient access to ixazomib.
Ixazomib is the first oral proteasome inhibitor (PI) licensed for use in Europe and, if reimbursed, would become part of the first Rd-based triplet regimen to be made available on the NHS to RRMM patients in England.
In the latest ACD, NICE acknowledged that triplet therapy is an emerging standard of care and that the data from the pivotal Phase III TOURMALINE-MM1 (TMM1) trial demonstrated that in patients treated with two or three prior therapies, the IRd regimen increased progression-free survival by approximately 9 months, when compared to the current standard of care in the UK (Rd). However, as data from the TMM1 trial is still maturing, NICE stated that the extent to which IRd prolongs overall survival compared with the current treatment for this patient group is uncertain.
Shelagh McKinlay, Policy and Public Affairs Officer at Myeloma UK, said: "This is very disappointing news for the myeloma community. Patients with myeloma need a novel, Rd-based triplet regimen; there are no others recommended for use by NICE and patients should be able to access this international standard of care on the NHS. We believe ixazomib clearly has the potential to be recommended for inclusion in the CDF which is supposed to provide access to innovative cancer drugs while further clinical evidence is gathered and used to demonstrate that these drugs are cost-effective – Takeda is collecting this data for ixazomib. We urge Takeda and NICE to work together collaboratively for a positive solution.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance